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a b s t r a c t
Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (serpin) that plays an important
role in cardiovascular disorders and tumor development. The potential role of PAI-1 as a drug target has
been evaluated in various animal models (e.g. mouse and rat). Sensitivity to PAI-1 inhibitory agents var-
ied in different species. To date, absence of PAI-1 structures from species other than human hampers
efforts to reveal the molecular basis for the observed species differences.
Here we describe the structure of latent mouse PAI-1. Comparison with available structures of human
PAI-1 reveals (1) a differential positioning of a-helix A; (2) differences in the gate region; and (3) differ-
ences in the reactive center loop position. We demonstrate that the optimal binding site of inhibitors may
be dependent on the orthologs, and our results affect strategies in the rational design of a pharmacolog-
ically active PAI-1 inhibitor.
 2010 Elsevier Inc. All rights reserved.
1. Introduction
Plasminogen activator inhibitor-1 (PAI-1) is the most important
physiological inhibitor of tissue-type plasminogen activator (t-PA)
and urokinase-type plasminogen activator (u-PA) (Kruithof et al.,
1984). It plays an important role in the regulation of the fibrino-
lytic activity in human blood (van Meijer and Pannekoek, 1995).
The relationship between increased PAI-1 levels and various vascu-
lar disorders such as venous thrombo-embolism, coronary artery
disease, myocardial infarction and atherosclerosis has been dem-
onstrated (Prins and Hirsh, 1991; Juhan-Vague et al., 1995;Wiman,
1999). In addition to its role in fibrinolytic processes, PAI-1 has
been demonstrated to be involved in a variety of other pathological
processes (Durand et al., 2004; Binder and Mihaly, 2008). Elevated
PAI-1 levels were also detected during wound healing, in rheuma-
toid arthritis, chronic stress, glomerulo-nephritis and gram-nega-
tive sepsis (Lijnen, 2005). A variety of studies have suggested
that PAI-1 may play a role in tumor growth and metastasis. This ef-
fect could be related either to its vitronectin-binding properties
(Declerck et al., 1988) or to its antiprotease properties (Bajou
et al., 1998). Furthermore, the importance of PAI-1 in vivo has been
demonstrated in studies using transgenic mice lacking (Carmeliet
et al., 1993) or overexpressing (Erickson et al., 1990) PAI-1.
PAI-1 is synthesized in the active form and binds to vitronectin
in plasma and in the extracellular matrix (Declerck et al., 1988).
PAI-1 spontaneously converts to the latent form under physiolog-
ical conditions with a half-life ranging between 90 and 120 min
(Hekman and Loskutoff, 1985). PAI-1 is a member of the serine
protease inhibitor (serpin) superfamily and is a single-chain, gly-
cosylated protein of approximately 50 kDa (379 amino acid resi-
dues). Up to now, three different conformations of PAI-1 have
been described: an active, a latent and a substrate conformation
(Hekman and Loskutoff, 1985; Declerck et al., 1992; Mottonen
et al., 1992; Munch et al., 1993; Sharp et al., 1999; Nar et al.,
2000). The tertiary structure of active PAI-1 shares motifs common
to most serpins, including the solvent-exposed reactive centre loop
(RCL) of about 20 amino acids long (designated P16 through P80,
including the bait peptide bond Arg346–Met347 (P1–P10)) (Motto-
nen et al., 1992). In its active conformation, this P1–P10 reactive
centre bond is cleaved upon reaction with a protease, followed
by an insertion of the amino terminal part of the RCL into b-sheet
A, hereby relocating the protease to the opposite pole of PAI-1
(Shore and Day, 1995). This results in the formation of a 1:1
SDS–stable acyl–enzyme complex (Egelund et al., 1998). During
this remarkable conformational change, the active site of the pro-
tease is distorted, and, as a consequence, the protease is inhibited
(Huntington et al., 2000; Dementiev et al., 2006). Upon latency
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conversion, the N-terminal part of the RCL from P16 to P3 is in-
serted into b-sheet A, forming the new b-strand 4A. Residues P2
to P80 of the RCL form an extended loop after latency transition.
The environment of the reactive center loop changes from sol-
vent-exposed to mostly buried, yielding the reactive center (P1–
P10) inaccessible for the target proteases (Mottonen et al., 1992).
Several human PAI-1 structures have been reported. The first
PAI-1 conformation that was structurally characterized was latent
PAI-1, elucidated in 1992 by Mottonen et al. (1992) (PDB entry
1C5G). Subsequently, two other groups elucidated a structure of
human PAI-1 in the latent conformation (Stout et al., 2000 (PDB en-
try 1DVN); Stein and Baek, 2002 (PDB entry 1LJ5)). The overall
pairwise rms deviation between all three structures is <0.45 Å,
showing the high structural homology across those structures.
These three structures originate from crystals with the same space
group, i.e. C2. Three structures of mutants of human PAI-1 in the
active conformation have been published (Sharp et al., 1999 (PDB
entry 1B3K); Nar et al., 2000 (PDB entry 1DB2); Stout et al., 2000
(PDB entry 1DVM)). All three structures are highly similar (pair-
wise rms deviation between all structures is <0.6 Å). Two struc-
tures originate form a crystal with a P1 space group, and one
from a crystal with a P3121 space group. Three structures of
cleaved, human PAI-1 variants have been reported (Aertgeerts
et al., 1995 (PDB entry 9PAI); Jensen and Gettins, 2008 (PDB entry
3CVM); Dewilde et al., 2009 (PDB entry 3EOX)). In addition, crystal
structures of human PAI-1 variants were elucidated in which PAI-1
is complexed with an inhibiting pentapeptide (corresponding to
P14–P10) (Xue et al., 1998) (PDB entry 1A7C) or with the somato-
medin B domain of vitronectin (Zhou et al., 2003) (PDB entry
1OC0).
All reported PAI-1 structures are derived from human PAI-1.
However, since PAI-1 is considered as an important potential drug
target in various diseases, its role has been evaluated in various
animal models, including mouse, rat and rabbit. Rodents are com-
monly used as research models because they are readily available
and relatively inexpensive. Disease pathogenesis in these animals
generally tends to approximate disease progression in humans,
although there is some divergence in cellular mechanism and path-
ogenesis (reviewed in Narayanaswamy et al. (2000) and Mestas
and Hughes (2004)). In addition, most animal proteins are not
identical to human proteins. Comparative evaluation of the puta-
tive therapeutic targets of different species is therefore of impor-
tance. The amino acid sequence identity between human PAI-1
(huPAI-1) and mouse PAI-1 (moPAI-1) is 78.9% (Fig. 1). Although
the stability and functional properties of PAI-1 of both species
are comparable (Xu et al., 2004), important species differences
have been observed with respect to their sensitivity to PAI-1 inhib-
itory agents (Cale et al., 2010). The lack of structures of PAI-1 from
other species has hampered efforts to unravel the molecular basis
for some of the observed species differences.
In this study, we describe the elucidation of the structure of
mouse PAI-1 (moPAI-1). A detailed comparison of this moPAI-1
structure with available structures of human PAI-1 (huPAI-1)
reveals three regions that are different between PAI-1 from these
two species. Some of these structural differences provide a molec-
ular explanation for previously described biochemical differences.
2. Materials and methods
2.1. Production of moPAI-1 and antibodies
Recombinant non-glycosylated moPAI-1 was expressed and
purified in a similar way as huPAI-1-wt described in Gils et al.
(1996). After purification, moPAI-1 was dialyzed against 50 mM
HEPES, pH 7.5, and 0.4 M NaCl. Mouse monoclonal antibody MA-
159M12 was produced as described elsewhere (Ngo et al., 2002).
2.2. Crystallization
Mouse PAI-1 samples were concentrated prior to crystallization
using a Vivaspin 15R (cutoff 10 kDa) concentrator. To determine
initial crystallization conditions, a selection of commercially avail-
able screens was applied (Hampton Research Crystal Screen 1 & 2,
Hampton Research Index Screen 1 & 2, Emerald BiosystemsWizard
Screen 1 & 2). The experimental setup was the hanging-drop va-
por-diffusion geometry using Linbro multi-well tissue plates,
stored at 277 K and/or 293 K. Each well was filled with 700 ll of
reservoir solution and each hanging drop consisted of 1.5 ll pro-
tein solution and 1.5 ll of reservoir solution, placed on coverslips
and set to equilibrate against these reservoir solutions. After
4 months, one crystal (400  200  50 lm) appeared in condition
81 of Hampton Research Index Screen (0.2 M Ammonium acetate,
0.1 M Tris, pH 8.5, 25% w/v PEG 3350, 277 K).
2.3. Data collection and data processing
Prior to flash-cooling in liquid nitrogen, the crystal was soaked
for 30 s in a drop containing the crystallization solution to which
20% glycerol had been added. Diffraction data collection was car-
ried out at the SLS synchrotron (Villigen, Switzerland) at 100 K
using a liquid-nitrogen stream. A complete diffraction dataset
could be collected to a resolution limit of 1.93 Å (Table 1). Data
were processed using XDS and XSCALE (Kabsch, 1993). The asym-
metric unit contains one monomer, with a Matthews coefficient of
Fig. 1. Amino acid sequence alignment of mouse and human PAI-1. Different amino
acids are indicated in red; secondary structure elements are indicated by the
respective arrows; the RCL is indicated by the pink arrow. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of
this article.)
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2.63 Å3 Da1 and a solvent content of 53%. Further statistics is
summarized in Table 1. The structure was phased by molecular
replacement in program PHASER using latent huPAI-1 (PDB entry
1DVN) as a search model (McCoy et al., 2007). Five percent of the
reflections were chosen at random as the test set for cross-valida-
tion during refinement. The initial search model was rebuild auto-
matically using ARP/wARP 7.0.1. Model rebuilding included the
adaptation of the huPAI-1 sequence to the moPAI-1 sequence
(Fig. 1). Further model optimization and restrained refinement
were done with COOT and REFMAC5, respectively (Emsley and
Cowtan, 2004; Murshudov et al., 1997). During refinement, trans-
lation, libration and screw-rotation (TLS) corrections were applied
(one TLS group). For the final refined structure, 98.9% of all residues
are located in the Ramachandran favored regions and all residues
are in the allowed regions. The final refinement statistics is shown
in Table 1. The final model was verified using Molprobity (Davis
et al., 2007), yielding an excellent Molprobity score (Table 1).
The final atomic model and diffraction data have been submit-
ted to the Protein Data Bank under the accession code 3LW2.
2.4. Construction and expression of moPAI-1 mutants
MoPAI-1-R4P, moPAI-1-D150H-K154T-Q319L and moPAI-1-
I91L were constructed using appropriate mutagenic primers. The
expression plasmid pIGE2-moPAI-1-wild-type (moPAI-1-wt) was
used as template. Site-directed mutagenesis was performed using
the QuikChange™ protocol (Stratagene, La Jolla, USA). Thermocy-
cling was conducted in an Eppendorf Mastercycler™ gradient ther-
mal cycler, using 50 ng of template and 20 lM of each mutant
primer. Denaturation, annealing and elongation were carried out
at 94 C, 55.6 C and 72 C, respectively. Subsequently, parental
template DNA was removed by DpnI and the mutated DNA was
transformed into DH1k Escherichia coli cells, followed by overnight
selection on agar plates containing tetracycline (10 lg/ml). For
large-scale DNA purification, a single colony was selected and
grown overnight in LB containing tetracycline (10 lg/ml) and the
DNA isolated using the Nucleobond™ AX 500 purification kit. The
presence of the introduced mutation as well as the absence of any
unwanted mutations was verified by nucleotide sequencing. The
expression and purification was similar as for moPAI-1-wt.
2.5. Characterization of moPAI-1 mutants
2.5.1. Affinity measurements
Binding measurements were performed by surface plasmon
resonance (SPR) analysis using BIAcore™ 3000 (Biacore AB, Upp-
sala, Sweden). The carboxymethylated dextran matrix of the CM5
sensor chip (CM5) was preactivated using N-hydroxysuccinimide
(NHS)/1-ethyl-3-[3-(dimethylaminopropyl) carbodiimide hydro-
chloride (EDC). Then, random amine coupling of the monoclonal
antibody to the chip was carried out by injecting the antibody at
a concentration of 5 lg/ml (10 mM sodium acetate, pH 4.5) with
a flow rate of 5 ll/min at 25 C, Subsequently, residual NHS esters
were deactivated by ethanolamine (1 M, pH 8.5). The antibodies
were covalently coupled to approximately 1200 resonance units.
One RU corresponds to 1 pg of bound protein/mm2. PAI-1 was di-
luted in HBS-EP buffer (Biacore) to concentrations between 5 and
200 nM and injected at a flow rate of 30 ll/min at 25 C. Associa-
tion and dissociation data were both collected for 6 min. After each
cycle, the chip was regenerated with 10 ll of 10 mM glycine, pH
1.5. Analysis of the association and dissociation rates was per-
formed using BIAevaluation version 3.1 software (Langmuir bind-
ing model, local fit) (Biacore). Data obtained from parallel flow
cells to which a monoclonal antibody against TAFI (MA-T1C10)
was coupled, served as blank sensorgrams for substraction of
changes in the bulk refractive index.
2.5.2. Functional stability
PAI-1 variants were diluted to concentrations between 0.1 and
0.2 mg/ml in the appropriate dilution buffer (final concentration;
0.025 M Na2HPO4 and 0.01% Tween 80, pH 7.2–7.4). The sample
was incubated at 37 C and aliquots removed at various time
points. Subsequently, aliquots were incubated (30 min, 37 C) with
a 2-fold molar excess of tPA. Samples were subjected to SDS–PAGE
(10–15% gels, non-reducing environment) and proteins were visu-
alized by staining with Coomassie Brilliant Blue. The conforma-
tional distribution (i.e. active/latent/substrate forms of PAI-1)
(Gils and Declerck, 1997) was determined by densitometric scan-
ning using Labscan™ and Imagemaster™ (GE Healthcare, Milwau-
kee, USA). The amount of active PAI-1 at various time points was
expressed as a percentage of the initial amount of active PAI-1
and the decay was used for the calculation of the half-life. Subse-
quently, the half-lives for inactivation were calculated with the
program Graph Pad Prism™ using ‘‘one phase exponential decay”
according to the equation: Y = span  e  K  X + plateau. The
half-life is then equal to 0.693/K.
To study the effect of MA-159M12 on the half-life, moPAI-1
variants were incubated with either an equal volume of PBS or a
3-fold molar excess of MA-159M12 at 37 C.
3. Results and discussion
3.1. Structural analysis
Since the crystallization took four months, the crystallized moP-
AI-1 was, not surprisingly, in the latent conformation. The final
electron density was of good quality throughout the model, except
for residues 346–356 (part of the RCL). However, as there was
sufficient experimental evidence about the conformation of these
residues, they were included in the final model (Fig. 2). Also (Mot-
tonen et al., 1992) observed higher B-factors for these residues in
Table 1
Data collection and refinement statistics for latent moPAI-1.
Data collection
Wavelength (Å) 0.9787
Resolution range (Å) 40–1.93 (1.98–1. 93)
Reflections
 Observed 225,021
 Unique 34,894
Completeness (%) 97.0 (95.5)
Average I/r 20.2 (4.3)
Rsym (%) 6.8 (47.4)
Crystal
Space group C2
Cell dimensions (Å, ) a = 150.9, b = 62.3, c = 52.2,
a = 90.0, b = 105.5, c = 90.0
Refinement
Number or atoms
 Protein 2926
 Solvent 227
Average B-factor (Å2)
 Protein 31.6
 Solvent 41.4
Rwork (%) 18.3
Rfree (%) 21.8
Reflections in the free’ set 1704
Rms deviations
 Bond lengths (Å) 0.011
 Bond angles () 1.361
Ramachandran plot (% residues in
favoured/disallowed regions)
98.9/0
Molprobity score 1.9
Values in parentheses are for the highest resolution shell.
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latent huPAI-1, indicating a less pronounced electron density. For
residues 1–6 and 189–196, there was no observable electron den-
sity at all, and hence these residues were omitted from the final la-
tent moPAI-1 structure. The rms deviation of Ca positions between
the refined latent moPAI-1 structure and latent huPAI-1 (PDB entry
1DVN) is 0.786 Å, indicating a high structural homology between
the two structures. However, superimposition of these two struc-
tures shows some local differences (Fig. 3).
3.2. a-Helix A region
The first region that differs substantially between latent human
and mouse PAI-1 is the a-helix A (hA) (Fig. 3). In all latent huPAI-1
structures (PDB entries 1C5G, 1DVN and 1LJ5), hA is located in ex-
actly the same position, which is clearly distinct from the position
in latent moPAI-1. Strikingly, the position of hA of latent moPAI-1
corresponds to the position of the hAs of all crystallized active hu-
PAI-1 monomers (PDB entries 1B3K, 1DB2 and 1DVM) (Fig. 4). The
first six amino acids of moPAI-1, corresponding to the N-terminus
of hA, could not be built in the final model due to poor electron
density maps for this region. Also the N-termini in all active hu-
PAI-1 crystal structures are not clearly defined. Although some of
the six N-terminal residues were built in for 1DB2 and 1DVM, their
B-factors (up to 100 Å2) suggest that these residues were not built
in unambiguously. In latent huPAI-1, the N-terminal end of hA is
bound to a-helix D (hD) by hydrophobic (P4–A74; P5–L78) and
electrostatic interactions (H3–E81). These interactions are not
possible in latent moPAI-1 where position three harbors a leucine,
position four an arginine and position five a glutamic acid. Conse-
quently, the lack of binding of hA to hD in moPAI-1 will render hA
more flexible, resulting in a lack of well-defined electron density in
the crystals. It remains unclear why hA of active huPAI-1 is not at-
tached to hD, despite the full sequence and structural homology in
this region for active and latent huPAI-1. Also the C-terminal part
of hA has a different conformation in both structures. It should
be noted that the crystal packing arrangement of mouse PAI-1 is
different from that of the latent human PAI-1 structure as exempli-
fied by the PDB structure 1DVN and may explain in part the ob-
served differences with regard to both the N- and C-termini of
helix A in both structures.
Previously, the epitope of a non-inhibitory monoclonal antibody
raised againsthuPAI-1wasmapped to theN-terminal regionof hAof
huPAI-1 (MA-31C9; residues H3, S6, Y7 and H10) (Gils et al., 2009).
Surprisingly, this region overlaps with the epitope of another, but
inhibitory, monoclonal antibody (i.e. MA-159M12) that was raised
against rat PAI-1 (KA = 3.0 ± 1.8  109 M1) but reacts with a low
affinity with moPAI-1 (KA = 0.07 ± 0.055  109 M1) (Ngo et al.,
2002). MA-159M12 binds to P2, L3, P4 and E5, located in hA, and ex-
erts a pronounced inhibitory effect by accelerating the active to la-
tent conversion of rat PAI-1. Thus, while sharing an epitope region,
antibodies MA-31C9 and MA-159M12 exert opposite functional ef-
fects (i.e. non-inhibitory vs. inhibitory). Rat and moPAI-1 share an
amino acid sequence homology of 93.4% (sequence identity of
89.4%). Based on this very high sequence homology, it is likely that
both structures are highly similar, including hA. MoPAI-1 harbors
P2, L3 and E5 as in rat PAI-1. To study the effects of MA-159M12
on moPAI-1, a proline at position four was introduced (moPAI-1-
R4P) to have all four important residues contributing to the epitope
of MA-159M12. As hypothesized moPAI-1-R4P exhibited an in-
creased affinity towards MA-159M12 (KA = 0.52 ± 0.14  109 M1)
and was susceptible to inhibition by MA-159M12 through a
decrease of the half-life (42 ± 8.4 min in the presence of a 3-fold
molar excess of MA-159M12 vs. 107 ± 3.5 min in the absence of
MA-159M12). Previous attempts to introduce the epitope of
MA-159M12 into hA of huPAI-1 did not succeed as this variant (hu-
PAI-1-H2P-H3L-P5E) exhibited an affinity (i.e. KA = 3.4  106 M1)
that is three orders of magnitude lower than that of rat PAI-1 (Gils
et al., 2009). Taken together all available data show that the position
of hA is similar in rat andmousePAI-1butdifferent compared to that
of hA in huPAI-1, consequently resulting in different functional ef-
fects ofmonoclonal antibodies that bind to this region: i.e. inhibitory
when binding to hA of mouse or rat PAI-1 vs. non-inhibitory when
binding to hA of huPAI-1.
3.3. Gate region
The second region in moPAI-1 with a different conformation
compared to huPAI-1 is the gate region (the loop connecting
b-strand s3C to b-strand s4C) (Fig. 3). This region is quite well
defined in all huPAI-1 structures whereas no electron density
was observed for this region in moPAI-1. This is indicative for a
much higher flexibility of the gate region in moPAI-1 compared
to huPAI-1. It is of interest to note that the gate region plays a role
in the active to latent transition (Aertgeerts et al., 1995; Engh et al.,
1993). The increased flexibility of the gate region in moPAI-1 may
be related to the observation that mutations known to stabilize
huPAI-1 do not have a similar effect on moPAI-1. To test this
hypothesis, mutations that stabilize active human PAI-1 (i.e.
N150H-K154T-Q319L-M354I) (Berkenpas et al., 1995) were
introduced into mouse PAI-1 (resulting in moPAI-1-D150H-
K154T-Q319L, since moPAI-1 has already an Ile at position 354).
HuPAI-1-N150H-K154T-Q319L-M354I has a 72-fold increased
half-life (145 h), compared to huPAI-1-wt (2 h). However, intro-
duction of the corresponding mutations in moPAI-1 resulted only
in a 2-fold increased half-life (i.e. 1.9 h vs. 3.6 h for moPAI-1-wt
and moPAI-1-D150H-K154T-Q319L, respectively) (Table 2). Alter-
natively a single mutation (Ile at position 91 to Leu) resulting in
9-fold increased half-life in huPAI-1 (huPAI-1-I91L, 18.4 h;
(Berkenpas et al., 1995) did not affect the stability of mo-PAI-1
(i.e. half-life of moPAI-1-I91L, 2.1 h). It should be noted that the
structural environment of mutations in both positions 150 and
154 is virtually identical in mouse and human PAI-1. However, res-
idue 319 adopts the same backbone position but its side chain is
interacting with the RCL for which substantial structural differ-
ences are observed (see below). Finally, the environment of residue
354 is distinctly changed as this residue is located in the RCL.
Taken together, the observed differential effects of these mutations
are indicative for relatively small structural differences associated
Fig. 2. Cartoon representation of moPAI-1. Beta sheet A is indicated in green (s1A–
s6A from right to left), a-helix A in blue, a-helix F in yellow and the reactive centre
loop is shown in red.
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with important differences in the properties of active moPAI-1 and
active huPAI-1 (e.g. as observed for the gate region in this study).
3.4. Reactive center loop
The third region with structural differences comprises the RCL
(Fig. 3). Although the central part of the RCL exhibits increased
temperature factors compared with the rest of the structure, the
N- and C-terminal portions of the RCL are well defined. Both por-
tions differ substantially from the conformation observed in latent
huPAI-1. N-terminally: the last residue of s4A in latent moPAI-1 is
F341 whereas in latent huPAI-1 s4A stretches till residue V343
(Fig. 5). C-terminally: the RCL is situated above of the C-terminus
in latent moPAI-1, whereas this is the other way around in latent
huPAI-1 (Fig. 6A). With the RCL being in this position in latent
moPAI-1, it is impossible for the gate region in latent moPAI-1 to
adopt the conformation as observed in latent huPAI-1, as it would
clash with the RCL (Fig. 6B). The different position of the RCL is also
correlated to the different conformation of the C-terminal part of
Fig. 3. Rms deviation between latent mouse PAI-1 and latent human PAI-1 vs. residue number. Ambiguous residues of the RCL were omitted.
Fig. 4. Comparison of a-helix A. Latent human PAI-1 (PDB entry 1DVN) is
represented in gray, latent moPAI-1 in yellow, active human PAI-1 (PDB entry
1BK3, chain A) in pink.
Table 2
Half-lives (h) of mouse PAI-1 mutants vs. human PAI-1 mutants.
Wild-type I91L 150/154/319/(354)a
Mouse 1.9 ± 0.3 2.1 ± 0.2 3.6 ± 1.0
Human 2.1 18.4 ± 1.1b 145.4 ± 1.0b
a Mutation D150H-K154T-Q319L(-M354I) (see text).
b Data taken from Berkenpas et al. (1995).
Fig. 5. Shorter b-strand s4A in moPAI-1. Latent moPAI-1 is indicated in yellow,
latent human PAI-1 in gray. In latent moPAI-1, a smaller portion of the RCL is
inserted as s4A, indicated in red.
Fig. 6. C-terminal portion of the RCL. Two different views related by a 60 rotation
are shown. Latent moPAI-1 is indicated in yellow, latent human PAI-1 in gray. The
C-termini of both PAI-1 structures are represented as spheres. For reasons of clarity
the gate region is omitted in (A).
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hA: in latent moPAI-1 hA is bent more to the core of the protein
compared to hA in latent huPAI-1 (Fig. 6A).
It is worth mentioning that another study (Xu et al., 2004)
reported a functional analysis of mutations in mouse PAI-1 demon-
strating that a mutation in the vitronectin-binding domain (Q123K)
or a mutation in the LRP-binding domain (R76E) of mouse PAI-1
abolished binding to vitronectin or LRP, respectively. Thus, these
mutations yield identical effects in mouse as in human PAI-1. This
is also in line with our current structural comparison, i.e. residues
73 and 123 are located in a region that is structurally not different
between mouse and human PAI-1.
In conclusion, although similar to human PAI-1, the elucidated
structure of moPAI-1 revealed some significant local differences.
Importantly, the observed structural differences could be con-
firmed by biochemical observations. This may have important con-
sequences in the rational design of LMW compounds for inhibition
of PAI-1. Indeed the current study demonstrates that extrapolation
of data for PAI-1 inhibition obtained in murine models should be
done with caution, as the optimal binding site of a LMW inhibitor
may be different for the different orthologs. In addition, this new
PAI-1 structure contributes to the knowledge on the structure–
function relationship in PAI-1. Detailed structural insights into this
therapeutic target are indispensable for the optimal design of a
pharmacologically active PAI-1 inhibitor.
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